Is ibrutinib associated with disseminated cryptococcosis with CNS involvement? Cancer Biol Ther 2019;20(2):138-140
Date
08/28/2018Pubmed ID
30148696Pubmed Central ID
PMC6343725DOI
10.1080/15384047.2018.1508622Scopus ID
2-s2.0-85053215351 (requires institutional sign-in at Scopus site) 7 CitationsAbstract
Chronic lymphocytic leukemia (CLL) is a disorder of B cells that affects humoral as well as cell-mediated immunity. Protection against cryptococcal infections is mounted by an intricate and synchronized interplay of both integral arms of immunity. Whether CLL or small molecule tyrosine kinase inhibitors are independently predisposing hosts to cryptococcal infections remain to be explored. Herein, we present a report of a patient who developed disseminated cryptococcosis while receiving ibrutinib therapy for CLL in the salvage setting. We further present relevant literature available thus far on the topic and discuss immunologic mechanisms that may be involved in the fungal pathogenesis in such patients.
Author List
Abid MB, Stromich J, Gundacker NDAuthor
Nathan D. Gundacker MD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdenineAged, 80 and over
Central Nervous System Neoplasms
Cryptococcosis
Humans
Male
Piperidines
Pyrazoles
Pyrimidines
